TempraMed closes $1.18M financing with debentures and units

TempraMed Technologies Ltd. (CSE:VIVI) has successfully closed a $1.18 million financing round, consisting of $600,000 in convertible debentures and 1,155,880 units, which include one common share and one warrant. The debentures have a 10% annual interest rate, payable quarterly in cash, and mature on September 30, 2027, with the option to convert into common shares at $0.50 per share before maturity.

The funds will be utilized for inventory, product development, scaling the sales and marketing division globally, and general working capital. The financing round follows previous announcements on September 23 and 28, 2026. TempraMed develops temperature-controlled medication storage solutions, including products like VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med, operating in North America, Europe, and Asia.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.